O	0	10	Randomized
O	11	16	phase
O	17	20	III
O	21	26	trial
O	27	29	of
B-intervention	30	40	marimastat
O	41	47	versus
B-control	48	55	placebo
O	56	58	in
B-eligibility	59	67	patients
I-eligibility	68	72	with
I-eligibility	73	83	metastatic
I-eligibility	84	90	breast
I-eligibility	91	97	cancer
I-eligibility	98	101	who
I-eligibility	102	106	have
I-eligibility	107	117	responding
I-eligibility	118	120	or
I-eligibility	121	127	stable
I-eligibility	128	135	disease
I-eligibility	136	141	after
I-eligibility	142	147	first
I-eligibility	147	148	-
I-eligibility	148	152	line
I-eligibility	153	165	chemotherapy
O	165	166	:
O	167	174	Eastern
O	175	186	Cooperative
O	187	195	Oncology
O	196	201	Group
O	202	207	trial
O	208	213	E2196
O	213	214	.

O	215	217	To
O	218	227	determine
O	228	235	whether
O	236	237	a
O	238	244	matrix
O	245	262	metalloproteinase
O	263	272	inhibitor
O	273	281	improves
O	282	293	progression
O	293	294	-
O	294	298	free
O	299	307	survival
O	308	309	(
O	309	312	PFS
O	312	313	)
O	314	316	in
O	317	325	patients
O	326	330	with
O	331	341	metastatic
O	342	348	breast
O	349	355	cancer
O	356	359	who
O	360	364	have
O	365	375	responding
O	376	378	or
O	379	385	stable
O	386	393	disease
O	394	399	after
O	400	405	first
O	405	406	-
O	406	410	line
O	411	423	chemotherapy
O	423	424	.

B-total-participants	425	428	One
I-total-participants	429	436	hundred
I-total-participants	437	444	seventy
I-total-participants	444	445	-
I-total-participants	445	449	nine
O	450	458	eligible
O	459	467	patients
O	468	472	were
O	473	481	randomly
O	482	490	assigned
O	491	493	to
O	494	501	receive
O	502	506	oral
O	507	517	marimastat
O	518	519	(
O	519	521	10
O	522	524	mg
O	525	528	bid
O	528	529	;
O	530	531	n
O	532	533	=
B-intervention-participants	534	537	114
O	537	538	)
O	539	541	or
O	542	543	a
O	544	551	placebo
O	552	553	(
O	553	554	n
O	555	556	=
B-control-participants	557	559	65
O	559	560	)
O	561	567	within
O	568	569	3
O	570	572	to
O	573	574	6
O	575	580	weeks
O	581	583	of
O	584	594	completing
O	595	598	six
O	599	601	to
O	602	607	eight
O	608	614	cycles
O	615	617	of
O	618	623	first
O	623	624	-
O	624	628	line
O	629	640	doxorubicin
O	640	641	-
O	642	645	and
O	645	646	/
O	646	648	or
O	649	655	taxane
O	655	656	-
O	656	666	containing
O	667	679	chemotherapy
O	680	683	for
O	684	694	metastatic
O	695	702	disease
O	702	703	.

O	704	712	Patients
O	713	717	were
O	718	727	evaluated
O	728	733	every
O	734	735	3
O	736	742	months
O	743	748	until
O	749	756	disease
O	757	768	progression
O	768	769	.

O	770	774	When
O	775	784	comparing
O	785	792	placebo
O	793	797	with
O	798	808	marimastat
O	808	809	,
O	810	815	there
O	816	819	was
O	820	822	no
O	823	834	significant
O	835	845	difference
O	846	848	in
B-outcome	849	852	PFS
O	853	854	(
O	854	860	median
O	860	861	,
B-iv-cont-median	862	863	3
I-iv-cont-median	863	864	.
I-iv-cont-median	864	865	1
I-iv-cont-median	866	872	months
O	873	874	v
B-cv-cont-median	875	876	4
I-cv-cont-median	876	877	.
I-cv-cont-median	877	878	7
I-cv-cont-median	879	885	months
O	885	886	,
O	887	899	respectively
O	899	900	;
O	901	907	hazard
O	908	913	ratio
O	913	914	,
O	915	916	1
O	916	917	.
O	917	919	26
O	919	920	;
O	921	923	95
O	923	924	%
O	925	927	CI
O	927	928	,
O	929	930	0
O	930	931	.
O	931	933	91
O	934	936	to
O	937	938	1
O	938	939	.
O	939	941	74
O	941	942	;
O	943	944	P
O	945	946	=
O	947	948	.
O	948	950	16
O	950	951	)
O	952	954	or
B-outcome	955	962	overall
I-outcome	963	971	survival
O	972	973	(
O	973	979	median
O	979	980	,
B-iv-cont-median	981	983	26
I-iv-cont-median	983	984	.
I-iv-cont-median	984	985	6
I-iv-cont-median	986	992	months
O	993	994	v
B-cv-cont-median	995	997	24
I-cv-cont-median	997	998	.
I-cv-cont-median	998	999	7
I-cv-cont-median	1000	1006	months
O	1006	1007	,
O	1008	1020	respectively
O	1020	1021	;
O	1022	1028	hazard
O	1029	1034	ratio
O	1034	1035	,
O	1036	1037	1
O	1037	1038	.
O	1038	1040	03
O	1040	1041	;
O	1042	1044	95
O	1044	1045	%
O	1046	1048	CI
O	1048	1049	,
O	1050	1051	0
O	1051	1052	.
O	1052	1054	73
O	1055	1057	to
O	1058	1059	1
O	1059	1060	.
O	1060	1062	46
O	1062	1063	;
O	1064	1065	P
O	1066	1067	=
O	1068	1069	.
O	1069	1071	86
O	1071	1072	)
O	1072	1073	.

O	1074	1082	Patients
O	1083	1090	treated
O	1091	1095	with
O	1096	1106	marimastat
O	1107	1111	were
O	1112	1116	more
O	1117	1123	likely
O	1124	1126	to
O	1127	1134	develop
B-outcome	1135	1140	grade
I-outcome	1141	1142	2
I-outcome	1143	1145	or
I-outcome	1146	1147	3
I-outcome	1148	1163	musculoskeletal
I-outcome	1164	1172	toxicity
I-outcome	1173	1174	(
I-outcome	1174	1177	MST
I-outcome	1177	1178	)
O	1178	1179	,
O	1180	1181	a
O	1182	1187	known
O	1188	1200	complication
O	1201	1203	of
O	1204	1207	the
O	1208	1212	drug
O	1213	1223	indicative
O	1224	1226	of
O	1227	1236	achieving
O	1237	1238	a
O	1239	1247	biologic
O	1248	1254	effect
O	1254	1255	,
O	1256	1264	compared
O	1265	1269	with
O	1270	1278	patients
O	1279	1291	administered
O	1292	1299	placebo
O	1300	1301	(
B-iv-bin-percent	1301	1303	63
I-iv-bin-percent	1303	1304	%
O	1305	1306	v
B-cv-bin-percent	1307	1309	22
I-cv-bin-percent	1309	1310	%
O	1310	1311	,
O	1312	1324	respectively
O	1324	1325	;
O	1326	1327	P
O	1328	1329	<
O	1330	1331	.
O	1331	1335	0001
O	1335	1336	)
O	1336	1337	.

O	1338	1346	Patients
O	1347	1351	with
O	1352	1357	grade
O	1358	1359	2
O	1360	1362	or
O	1363	1364	3
O	1365	1368	MST
O	1369	1372	had
O	1373	1386	significantly
O	1387	1395	inferior
B-outcome	1396	1404	survival
O	1405	1413	compared
O	1414	1418	with
O	1419	1427	patients
O	1428	1431	who
O	1432	1435	had
O	1436	1441	grade
O	1442	1443	0
O	1444	1446	or
O	1447	1448	1
O	1449	1452	MST
O	1453	1454	(
O	1454	1460	median
O	1460	1461	,
B-iv-cont-median	1462	1464	22
I-iv-cont-median	1464	1465	.
I-iv-cont-median	1465	1466	5
I-iv-cont-median	1467	1473	months
O	1474	1475	v
B-cv-cont-median	1476	1478	28
I-cv-cont-median	1478	1479	.
I-cv-cont-median	1479	1480	2
I-cv-cont-median	1481	1487	months
O	1487	1488	;
O	1489	1490	P
O	1491	1492	=
O	1493	1494	.
O	1494	1496	04
O	1496	1497	)
O	1497	1498	.

O	1499	1501	In
O	1502	1510	addition
O	1510	1511	,
O	1512	1520	patients
O	1521	1524	who
O	1525	1528	had
O	1529	1530	a
O	1531	1541	marimastat
O	1542	1548	plasma
O	1549	1562	concentration
O	1563	1565	of
O	1566	1568	at
O	1569	1574	least
O	1575	1577	10
O	1578	1580	ng
O	1580	1581	/
O	1581	1583	mL
O	1584	1586	at
O	1587	1592	month
O	1593	1594	1
O	1595	1598	and
O	1598	1599	/
O	1599	1601	or
O	1602	1603	3
O	1604	1608	were
O	1609	1622	significantly
O	1623	1627	more
O	1628	1634	likely
O	1635	1637	to
O	1638	1642	have
B-outcome	1643	1648	grade
I-outcome	1649	1650	2
I-outcome	1651	1653	to
I-outcome	1654	1655	3
I-outcome	1656	1659	MST
O	1660	1661	(
O	1661	1662	P
O	1663	1664	<
O	1665	1666	.
O	1666	1670	0001
O	1670	1671	)
O	1671	1672	.

O	1673	1683	Marimastat
O	1684	1688	does
O	1689	1692	not
O	1693	1700	prolong
B-outcome	1701	1704	PFS
O	1705	1709	when
O	1710	1714	used
O	1715	1720	after
O	1721	1726	first
O	1726	1727	-
O	1727	1731	line
O	1732	1744	chemotherapy
O	1745	1748	for
O	1749	1759	metastatic
O	1760	1766	breast
O	1767	1773	cancer
O	1773	1774	.

O	1775	1783	Patients
O	1784	1788	with
O	1789	1795	higher
O	1796	1806	marimastat
O	1807	1813	levels
O	1814	1823	exhibited
O	1824	1827	MST
O	1827	1828	,
O	1829	1832	and
O	1833	1836	MST
O	1837	1840	was
O	1841	1851	associated
O	1852	1856	with
O	1857	1865	inferior
O	1866	1874	survival
O	1874	1875	.
